Originally published In Press as doi:10.1074/jbc.M201208200 on August 9, 2002
J. Biol. Chem., Vol. 277, Issue 52, 50237-50244, December 27, 2002
Peroxisome Proliferator-activated Receptor
(PPAR
)
Influences Substrate Utilization for Hepatic Glucose Production*
Jun
Xu
§¶,
Gary
Xiao
§,
Chuck
Trujillo
§,
Vicky
Chang
§,
Lilia
Blanco
§,
Sean B.
Joseph
,
Sara
Bassilian**,
Mohammed F.
Saad§,
Peter
Tontonoz

§§,
W. N. Paul
Lee**, and
Irwin J.
Kurland
§
¶¶
From the § Department of Medicine, the
Laboratory of Metabolomics, the ¶ Department of
Biological Chemistry, the
Department of Pathology, David
Geffen School of Medicine at UCLA, Los Angeles, California
90095, 
Molecular Biology Institute,
UCLA, Los Angeles, California 90095, and the ** Department of
Pediatrics, Harbor-UCLA Medical Center,
Torrance, California 90502
Received for publication, February 6, 2002, and in revised form, August 6, 2002
 |
ABSTRACT |
The hypoglycemia seen in the fasting
PPAR
null mouse is thought to be due to impaired liver fatty acid
-oxidation. The etiology of hypoglycemia in the PPAR
null mouse
was determined via stable isotope studies. Glucose, lactate, and
glycerol flux was assessed in the fasted and fed states in 4-month-old
PPAR
null mice and in C57BL/6 WT maintained on standard chow using a
new protocol for flux assessment in the fasted and fed states. Hepatic
glucose production (HGP) and glucose carbon recycling were estimated
using [U-13C6]glucose, and HGP,
lactate, and glycerol turnover was estimated utilizing either
[U-13C3]lactate or
[2-13C]glycerol infused subcutaneously via Alza
miniosmotic pumps. At the end of a 17-h fast, HGP was higher in the
PPAR
null mice than in WT by 37% (p < 0.01).
However, recycling of glucose carbon from lactate back to glucose was
lower in the PPAR
null than in WT (39% versus 51%,
p < 0.02). The lack of conversion of lactate to
glucose was confirmed using an
[U-13C3]lactate infusion. In the fasted
state, HGP from lactate and lactate production were decreased by 65 and
55%, respectively (p < 0.05) in PPAR
null mice. In contrast, when [2-13C]glycerol
was infused, glycerol production and HGP from glycerol increased by 80 and 250%, respectively (p < 0.01), in the fasted state of PPAR
null mice. The increased HGP from glycerol was not
suppressed in the fed state. While little change was evident for
phosphoenolpyruvate carboxykinase (PEPCK) expression, pyruvate kinase
expression was decreased 16-fold in fasted PPAR
null mice as
compared with the wild-type control. The fasted and fed insulin levels
were comparable, but blood glucose levels were lower in the PPAR
null mice than in controls. In conclusion, PPAR
receptor function
creates a setpoint for a metabolic network that regulates the rate and
route of HGP in the fasted and fed states, in part, by controlling the
flux of glycerol and lactate between the triose-phosphate and
pyruvate/lactate pools.
 |
INTRODUCTION |
The transition through the fasting and refeeding cycle is an
important metabolic adaptation in response to food availability and
food intake. The adaptation allows the optimization of fuel energy
substrate utilization switching from a glucose-and-fatty acid oxidation
to a glucose-and-fatty acid storage state. It is believed that these
metabolic changes are effected by the reciprocal action of insulin and
glucagon. However, the recent availability of animals with specific
nuclear receptor disorders, such as the PPAR
KO mice, have drawn
attention to the linkage between the regulation of fatty acids by the
nuclear receptor family and glucose metabolism. PPAR
is a member of
the nuclear hormone receptors, the peroxisome-proliferator-activated
receptors (PPARs),1 for which
fatty acids are ligands (reviewed in Refs. 1, 2). PPAR
controls the
expression of a number of genes involved in mitochondrial and
peroxisomal
-oxidation and plays an important role in maintaining
energy homeostasis (reviewed in Refs. 1, 2) during fasting. PPAR
KO
mice, fasted for 24 h, exhibit severe hypoglycemia, ketonuria,
hypothermia, and elevated free fatty acids (FFA) (3, 4). The etiology
of the fasting hypoglycemia has not been well characterized. Studies of
changes in mRNA expression for the gluconeogenic enzymes
phosphoenolpyruvate carboxykinase (PEPCK) and G6Pase p36 catalytic
subunit from fast to fed state showed a lack of causal relationship
between gluconeogenic enzymes and the observed hypoglycemia (3, 5).
In vivo studies to establish the relationship between
PPAR
and insulin action showed that the absence of PPAR
did not
affect the insulin tolerance test (6) and intraperitoneal glucose
tolerance test (3, 6) when wild-type and PPAR
null mice were
maintained on a chow diet.
The etiology for the hypoglycemia seen in the fasting PPAR
null
mouse is believed to reflect a depletion of liver glycogen and a
decrease in gluconeogenesis secondary to impaired liver fatty acid
-oxidation (3, 4). We report here a study of the regulation of HGP
and substrate utilization for PPAR
null mice maintained on a chow
diet, during the physiologic situation of a moderate overnight fast (17 h) and refeeding (5 h), using 13C-mass isotopomer
distribution analysis (MIDA). The measurement of substrate flux
utilization is based on the novel use of the Alza miniosmotic pump to
supply a continuous infusion of one of three tracers,
[U-13C6]glucose,
[U-13C3]lactate, or
[2-13C]glycerol. This form of metabolomic profiling
uncovers the "silent" phenotype not seen in previous studies of
PPAR
KO mice and insulin action and indicates that PPAR
is an
important element regulating metabolic transition from fed to fasted
states. The data indicate that the actions of PPAR
intersect with
those of insulin in the regulation of substrate utilization for hepatic
glucose production.
 |
MATERIALS AND METHODS |
Animal Studies--
The PPAR
/
mice on a C57BL/6
background were a generous gift from Frank J. Gonzalez and have been
described (6). The PPAR
+/+ mice (C57BL/6) were obtained from
colonies maintained by the National Institutes of Health. Animal
studies were conducted in accordance with the ILACUC guidelines after
approval by our Institutional Review Board. All experiments were
performed with male mice ranging from 16 to 18 weeks in age. The
average weight of the PPAR
+/+ mice was 25.7 ± 1.9 grams, and
the average weight of the PPAR
/
mice was 29.9 ± 5 grams.
All mice were maintained on standard chow (NIH-31 sterilizable diet
7013, purchased from Harlan Teklad, Madison, WI).
Fasting was initiated at 5 p.m. An Alza miniosmotic pump (model
2001D, Alza, Palo Alto, CA) was inserted between 7 and 8 p.m. The
pump contained either 60 mg of [2-13C]glycerol, 50 mg of
[U-13C3]lactate, or 50 mg of
[U-13C6]glucose, each dissolved in 200 µl
of water. The quantity of tracer is sufficient to last through the
experiment infusing at a factory-calibrated pump rate of 8 µl per
hour. The minipump is inserted in the subcutaneous space, and therefore
infusion conditions approximate those of the venous-arterial (V-A) mode of infusion and sampling. Plasma glucose, lactate, and glycerol were
sampled in the fasting state between 10 am 11 am. The mice undergoing
an [U-13C6]glucose study were sacrificed in
the fasting state. The mice undergoing the
[2-13C]glycerol and
[U-13C3]lactate studies were then refed
standard chow (NIH-31 sterilizable diet 7013) and sacrificed between 3 and 4 pm. The animals consumed virtually all of their chow eaten within
2 h of refeeding. At the time of sacrifice, animals were killed by
an overdose of isoflurane anesthesia, and tissue from liver and
skeletal muscle were rapidly dissected free, snap-frozen in liquid
nitrogen, and stored at
80 °C until processed for isolation of RNA
or glycogen.
RNA Extraction and Analysis--
Total RNA was prepared from
~100 mg of liver after extraction with a guanidinium HCl/phenol
mixture (7) following Roche Molecular Biochemicals Tripure Isolation
Reagent protocol. Typically, 100 µg of total RNA are obtained from
one extraction.
Assessment of Pyruvate Kinase and PEPCK Enzyme mRNA Levels by
TAQMAN RT-PCR--
The TAQMAN system is designed to have a
fluorescent- and quencher-tagged probe bind to the region amplified
between the forward and reverse primers for the cDNA amplification
reaction (after the RT step). The TAQ polymerase hydrolyzes the probe
during the extension reaction, releasing the fluorescent tag from the
proximity of the quencher, and thereby each amplification cycle can be
detected allowing for the accurate, quantitative determination of the
linear region of RT-PCR amplification. Specifically, the number of
cycles necessary to reach the threshold for linear amplification of the cDNA (the CT value) is obtained. The
2
CT reflects the total mRNA
abundance for a given target RNA, the higher the CT
the lower the abundance of the target mRNA. Normalization of
the target mRNA to a housekeeping reference is given by
2
CT/2
CR
or
2(CR
CT) = 2
CT. When this result is
normalized to a baseline, as for example a Me2SO
control for an experiment with insulin-signaling inhibitors dissolved
in Me2SO, the relative abundance of the target mRNA to
the housekeeping reference mRNA, normalized to the
Me2SO control, is 2
CT
condition/2
CT
Me2SO = 2
CT. This RT-PCR system affords
easy screening with only ~100 ng needed for each measurement, which
are done in triplicate for accuracy. In all RT-PCR assessments,
measures were taken to avoid amplification of a region of genomic DNA
or other contaminants. Target and reference RT-PCR reactions (for
example, PEPCK as a target and
-actin for reference) were run singly
and then together as a multiplex reaction. The primer concentrations
were adjusted in the multiplex reaction tube such that accurate
CT values are obtained, but soon after, the
exhaustion of primers defines the end of the reaction. In this way,
amplification of the majority species is stopped before it can
limit reactants available for amplification of the minority
species. Table I shows the primer pairs and labeled probes used in these TAQMAN RT-PCR studies.
View this table:
[in this window]
[in a new window]
|
Table I
TAQMAN Primer and Probe Design
The TAQMAN system is designed to have a fluorescent and quencher tagged
probe bind to the region amplified between the forward and reverse
primers for the cDNA amplification reaction (after the RT step).
The TAQ polymerase hydrolyzes the probe during the extension reaction,
releasing the fluorescent tag from the proximity of the quencher, and
thereby each amplification cycle can be detected, allowing for the
accurate, quantitative determination of the linear region of RT-PCR
amplification. The fluorescent tag is attached to the 5' end of the
TAQMAN probe, and the quencher tag (TAMRA) is attached to the 3' end of
the TAQMAN probe. The fluorescent tag FAM was used for pyruvate kinase
and PEPCK, and VIC was used for -actin, allowing for sufficient
spectral differentiation so that pyruvate kinase/ -actin or
PEPCK/ -actin RT-PCR reactions could be run as multiplex reactions
within the same tube.
|
|
Biochemical Analyses--
Plasma glucose and lactate
concentrations were determined by COBAS MIRA analyzer (Roche Molecular
Biochemicals) using reagents provided by Raichem (San Diego, CA).
Glucose UV Reagent (Catalog no. 80017) was used for glucose
determination, and Stat-Pack Rapid Lactate Test (Catalog no. 869218)
was used for lactate. Liver and muscle glycogen were determined after
liver or muscle tissues were homogenized and then sonicated in 0.1 N sodium acetate buffer, pH 4.5 (1 ml of buffer/100 mg of
tissue). The resulting homogenates were incubated with amylglucosidase
(Roche Molecular Biochemicals) overnight at 37 °C. Cellular debris
was removed by centrifugation. The supernatant containing glycogen
glucose was then desalted using both anion and cation exchange columns
(Dowex-1 and Dowex-50, Sigma). The concentration of glucose in the
neutral fraction was determined for the calculation of liver or muscle
glycogen and for gas chromatography/mass spectrometry (GC/MS) analysis.
The amount of liver or muscle glycogen is calculated and reported as
µg of glucose/mg of liver or muscle. Stable isotopes (99% enriched) were purchased from ISOTEC (Miamisburg, OH).
Derivatization of Metabolites for GC/MS
Analysis--
100-150 µl of blood plasma was deproteinized,
deionized, and dried. Liver or muscle glycogen glucose extract was also
dried. The glucose and glycerol were treated with hydroxylamine
hydrochloride and then acetic anhydride to create aldonitrile
pentaacetate derivatives for GC/MS analysis according to a modification
of the method of Szafranek et al. (8). The procedure
converts glucose to its aldonitrile pentaacetate derivative and
glycerol into its triacetyl ester derivative. The resulting glucose or
glycerol derivative was dissolved in 150 µl of ethyl acetate for
GC/MS analysis. Lactate was extracted with ethyl acetate and converted
to its lactic acid n-propylamide-heptafluorobutyric ester according to
the method of Tserng et al. (9). The lactate derivative was
dissolved in 150 µl of methylene chloride for GC/MS analysis.
GC/MS--
All isotopomeric determinations were
performed on a Hewlett Packard Mass Selective Detector (model 5973A)
connected to a Hewlett Packard Gas Chromatograph (model 5890) using
either chemical ionization (for glucose, glycerol, and lactate
derivatives) or electron impact ionization (for glucose derivative
only) (8). Glucose and glycerol derivatives were separated on a HP5
capillary column, 30 meters × 250 micrometers internal diameter.
GC conditions were helium as carrier gas at a flow rate of 1.0 ml/min;
sample injector temperature was 250 °C; and oven temperature was
programmed from 220 to 250 °C at a ramp of 10 °C/min. The
retention time for the glucose aldonitrile pentaacetate was 2.9 min.
Different temperature programming was used for glycerol (from 140 to
230 °C at a ramp of 20 °C/min) and lactate (from 100 to 160 °C
at a ramp of 20 °C/min). Retention times were 5.2 min and 3.9 min
for the glycerol and lactate, derivatives respectively.
Chemical ionization conditions were with 20% methane. The glucose
aldonitrile pentaacetate derivative gives the molecular ion (C1-C6) of
the glucose molecule at m/z 328. Electron impact ionization of the aldonitrile derivative was used to characterize glucose positional isotopomers at m/z 187 for
C3-C6 and m/z 242 for C1-C4 fragments. The ion
clusters monitored for glycerol acetyl ester were from
m/z 158 to m/z 164 with
m/z 159 corresponding to unlabeled glycerol.
Selected ion monitoring was used to follow specific ions. For glucose
isotopomer determination, the ion clusters monitored were from
m/z 327 to m/z 336 with a
fragment of m/z 328 corresponding to unlabeled
glucose. The ion clusters monitored for lactate isotopomers were from
m/z 327 to m/z 332 with a
fragment of m/z 328 corresponding to unlabeled lactate.
Data Calculation and Interpretation--
Mass isotopomer
distribution is determined using the method of Lee et al.
that corrects contribution of derivatizing agent and natural
13C abundance to mass isotopomer distribution of the
compound of interest (10, 11). The method also corrects for the
presence of small amounts of M4 and M5 in the infused
[U13C6]glucose. Results of the mass
isotopomers in glucose, glycerol, or lactate are reported as molar
fractions of m0, m1, m2, etc. according to the number of labeled
carbons in the molecule (10, 11). The enrichment of a certain
13C-labeled molecule is defined as its molar fraction
mi, the fraction of molecules with i
being the number of 13C substitutions.
mi = labeled molecules with i being the 13C/(total number of molecules). The sum of all
isotopomers of the molecules,
mi for
i = 0 to n (n = 3 or 6 for
lactate/glycerol or glucose, respectively), is equal to 1 or 100%.
Calculation of Production Rates (PR)--
Substrate production
or turnover rates were determined using the principle of tracer
dilution. At isotopic steady state, the production rate of a substrate
is given by the following general equation (reviewed in Ref.
12).
|
(Eq. 1)
|
In the case of glucose production rate, HGP = working pump
rate × [(isotope enrichment)/(final substrate enrichment) -1]. The "correction" mentioned under "Materials and Methods" (10, 11) adjusts the impurities in the administered
[U-13C6]glucose infused so that the
enrichment can be considered to be 100%. M6 = final substrate
enrichment.
|
(Eq. 2)
|
Similarly, glycerol production rate (mg/min/kg) can be
calculated as in the following equation.
|
(Eq. 3)
|
Lactate production rate can be calculated as in the following
equation.
|
(Eq. 4)
|
Note that capital M represents molar fraction of glucose;
lowercase m represents molar fraction of glycerol or lactate. It should
be noted that except for the glucose production rate, the estimation of
the lactate and glycerol production rate is dependent on the site of
infusion and site of sampling. Since the minipumps were inserted
subcutaneously, the experimental conditions approximate those of a V-A
mode of infusion and sampling. The lactate and glycerol production rate
obtained by such a V-A mode of infusion and sampling is known to be
less than the rate obtained by the A-V mode of infusion and sampling
(13, 14).
Calculation of Glucose Molecule Recycling--
The basis for
calculation of glucose molecule recycling has been extensively
discussed by Landau et al. (15, 16). Theoretically, one
molecule of [U-13C6]glucose is converted into
two molecules of [U-13C3]lactate/pyruvate
through glycolysis. The [U-13C3]lactate can
be reutilized for gluconeogenesis such that one molecule of m3 lactate
can be recycled as m1, m2, or m3 phosphoenolpyruvate (PEP). We
therefore calculated the glucose molecule recycling (FRC) using m1, m2,
and m3 isotopomers of lactate and M1, M2, and M3 isotopomers of glucose
using the formula of Landau et al. (16).
|
(Eq. 5)
|
The fractional contribution of glucose to lactate synthesis = 1/DL.
|
(Eq. 6)
|
Combining Equations 5 and 6, the fractional contribution (FRC)
of the newly synthesized glucose recycled from lactate is shown in the
following equation.
|
(Eq. 7)
|
Calculation of Fractional Contribution of Lactate and Glycerol to
Gluconeogenesis--
The concept of glucose molecule recycling via
lactate can be applied to [U-13C3]lactate and
[2-13C]glycerol infusion studies. Fractional contribution
from lactate (Lactate FRC) is given by the following two equations.
|
(Eq. 8)
|
|
(Eq. 9)
|
Similarly, fractional contribution from glycerol (Glycerol FRC)
is given by the following equation.
|
(Eq. 10)
|
|
(Eq. 11)
|
Since lactate and glycerol production rates may be
underestimated by the V-A mode of infusion and sampling, such
underestimation may result in similar underestimation of their
contribution to gluconeogenesis (14).
Calculation of Fractional Gluconeogenesis by MIDA--
When high
amounts of [2-13C]glycerol is infused, the condensation
of two labeled glycerol molecules (via triose-P) in gluconeogenesis results in three isotopomer species M0, M1, and M2 of glucose. From the
distribution of glucose isotopomers, it is possible to deduce precursor
(triose-P) enrichment (p) and fraction of new glucose (FSR) using
combinatorial algebra (reviewed in Ref. 17).
|
(Eq. 12)
|
The fractional contribution of glycerol to the triose-P pool can
be calculated when plasma glycerol enrichment (glyE) is determined. It
is given by the following expression.
|
(Eq. 13)
|
The fractional glucose synthesis rate due to gluconeogenesis
(FSR) can be determined by
|
(Eq. 14)
|
This calculated FSR has been shown to be independent of the mode
of infusion and sampling because the recombination occurs at the site
of synthesis and is not dependent on the enrichment at the site of
sampling (14). The difference between FSR and FRC from lactate or
glycerol is that FSR describes how much newly synthesized glucose comes
from triose-P pool, while FRC describes how much of this newly
synthesized glucose comes from glycerol or lactate. Thus,
theoretically, FSR is always greater than FRC.
Statistical Analyses--
Analyses for the significance of
differences were performed using Student's t test, except
for analyzing whether steady state isotopomer enrichments occurred in
the fasted state (Fig. 1). For the data in Fig. 1, analysis of variance
with Tukey's post-test was used.
 |
RESULTS |
In our paper, the results of lactate turnover and glycerol
turnover as well as their contribution to glucose production were calculated based on the V-A mode. Comparison between PPAR knockout and
wild-type is based on the same V-A mode. As noted by Beylot and
co-workers in their recent paper (14) in the rat, glycerol turnover
rate as well as the percent contribution of glycerol to total glucose
production is higher in the A-V mode than those obtained from the V-A
mode. This trend has also been extensively documented for lactate
infusion. However, the ease of surgery (~3 min local procedure for
minipump placement) and freedom of unrestricted movement after minipump
placement make up for any possible increase in measurement of turnover
rates from an A-V method. The A-V method would require more extensive
surgery and stress due to excessive blood draws needed for the standard
euglycemic-hyperinsulinemic clamp procedure, as well as stress due to
restricted movement in a small rodent such as a mouse.
Glucose Homeostasis in the Fasted and Fed States--
The WT mice
were able to maintain a normal blood glucose concentration of 122 mg/dl
after an overnight fast (Table II). The level increased to 251 mg/dl 5 h after feeding. The PPAR
KO
mice had lower plasma glucose than WT controls in both the fasted and fed states (Table II). There was no significant difference in fasted or
fed insulin levels between the PPAR
KO mice and the WT controls. The
low plasma glucose in the PPAR
KO mice was associated with normal
lactate levels in the fasted and fed states. Glycogen content in the
liver and muscle of the PPAR
KO mice was lower than that of the
control WT mice in the fed state, but no difference was seen for both
strains in the fasted state.
View this table:
[in this window]
[in a new window]
|
Table II
Biochemical data for WT-C57BL/6 and PPAR KO mice
Mice were fasted for 17 hours and refed standard laboratory chow for 5 hours. Statistical comparisons are between fasted values or fed values
only; fed and fasted values are not compared. * and
# indicate p < 0.001. ** indicates p < 0.01. For fasted and fed
glycogen levels, the numbers represent an average for all mice used,
regardless of tracer. See "Material and Methods" for measurement
techniques.
|
|
Since the Alza miniosmotic pump has not previously been used for tracer
infusion in metabolic studies, we have carried out separate experiments
to demonstrate the achievement of isotopic steady state of both the
fasted and refed studies. Fig. 1 shows the M6 and M3 enrichment in glucose and m3 enrichment in lactate after
an overnight [U-13C6]glucose infusion. Plasma
m3 lactate is very constant between 15-19 h of infusion. There is no
statistically significant difference in the M6 glucose enrichment or in
the conversion of M6 to M3 glucose. Fig.
2 shows the time course of the enrichment
of the m1 glucose, m1 lactate, and m1 glycerol in the 17-h fasted and refed states in response to an overnight constant infusion of [2-13C]glycerol by the minipumps. The achievement of
metabolic and isotope steady state, between 4 and 5 h after
refeeding, is evident.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
Mass isotopomer enrichment in glucose and
lactate after an overnight infusion of
[U-13C6]glucose
administered by Alza miniosmotic pump (see "Materials and Methods")
in 4-month-old C57BL/6 (background strain) mice. Isotopic steady
state of glucose and lactate enrichments is attained at 15, 17, and
19 h of infusion during the fast. The variability in isotopomer
enrichments seen from the expanded y-axis scales used can be
expected from the relatively small number of mice used for each point
(n = 3); however, no statistically significant
differences were evident by analysis.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Mass isotopomer enrichment in glucose and
lactate after an overnight infusion of
[2-13C]glycerol administered by Alza
miniosmotic pump (see "Materials and Methods") in 4-month-old
C57BL/6 (background strain) mice. n = 3 for each
time point. Glucose, glycerol, and lactate enrichments after
[2-13C]glycerol infusion were measured 17 h into the
fast (0 h), and 2, 3, 4, and 5 h after refeeding of a mixed meal.
Isotopic steady state is seen between 4 and 5 h after
refeeding.
|
|
Table III shows HGP, dilution of blood
glucose carbon, and fractional contribution of lactate to glucose as
measured by the dilution and recycling of
[U-13C6]glucose. The enrichment of M6 glucose
in the 17-h fasted state was 30% higher in WT control than in the
PPAR
KO, and correspondingly the calculated HGP is 37% higher in
the PPAR
KO than in the WT. The increase in HGP seen for the PPAR
KO mouse raises the question whether the increased HGP is secondary to
gluconeogenesis, and if so, what are the major gluconeogenic substrates
used when PPAR
is absent? Examining glucose carbon recycling
provides part of the answer. The fasted glycogen levels are the same,
statistically, between the PPAR
KO and the WT control so tracer
dilution differences are not a factor. The breakdown of
[U-13C6]glucose results in the formation of
m3 triose phosphate/lactate, and the reconversion of m3 triose
phosphate/lactate back to glucose leads to labeled glucose with three
13C carbons (M3 glucose). Using the assumption that every
labeled lactate molecule recycles as another labeled molecule in
glucose (Equation 8), we calculated the recycling of labeled lactate. In the fasted state, 51% of glucose carbons were recycled in the WT,
as compared with 39% of glucose carbons in the PPAR
KO. The lower
recycling in PPAR
KO indicates the presence of a partial block in
the conversion of lactate to glucose.
View this table:
[in this window]
[in a new window]
|
Table III
Glucose production and conversion for WT-C57BL/6 and PPAR
KO mice
Mice were fasted for 17 hours. * indicates p < 0.01, and ** indicates p < 0.02. See
"Materials and Methods" for formulas used for calculation of
substrate production and conversion.
|
|
The decrease in the muscle glycogen store for the PPAR
KO mouse is
expected to contribute to a smaller dilution of blood glucose-labeled
carbons. This effect is seen in the dilution factor of blood lactate.
When a mole of [U-13C6]glucose undergoes
glycolysis, 2 moles of m3 lactate is formed. The lactate dilution
factor reflects the dilution of labeled lactate by unlabeled lactate,
resulting from the metabolism by unlabeled glycogen-glucose to lactate
by muscle, for example, in the transition between the fed and fasted
states. The reciprocal of blood glucose contribution to lactate is the
lactate dilution factor, DL (see "Materials and
Methods"), which is correspondingly decreased in the PPAR
KO.
Note, that both fed liver and muscle glycogen are lower in the
measurements seen for the PPAR
KO mice (Table II), in agreement with
less dilution seen in the fasted state. In the WT mice, blood glucose
contributed about 51% of the lactate in circulation (1/1.95 × 100, see Table III). This contribution was higher in the PPAR
KO
being 66% (1/1.52 × 100, see Table III). The product of lactate
dilution factor, DL, and the glucose carbon recycling, F,
reflects gluconeogenesis from blood lactate. Gluconeogenesis from
lactate is almost 100% in the WT in contrast with 59% in the PPAR
KO. Gluconeogenesis was further studied using a
[2-13C]glycerol infusion. The combination of two labeled
triose-P to form glucose with two 13C carbons (M2 glucose)
was exploited to determine precursor enrichment and gluconeogenic
fraction of the glucose synthesis rate (FSR). The results are shown in
Fig. 3. In the fasted state, FSR
approached 100% in both WT and PPAR
KO. In the fed state, the FSR
was suppressed in the WT controls, which could be an effect by insulin,
dilution of isotopomer enrichments by unlabeled glucose coming from the gut, or from glycogenolysis in the liver. However, no decrease in the
FSR is seen for the PPAR
KO mice, resulting in a relative increase
of 170% in the FSR in the fed state for the PPAR
KO mouse.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Shown is the fractional glucose synthesis
rate due to gluconeogenesis (FSR, see Equation 14) measured in the 17-h
fasted state and after 5 h of refeeding for the PPAR KO mice
and WT C57BL/6 control using a [2-13C]glycerol infusion
administered by Alza miniosmotic pump (see "Materials and
Methods"). FSR percentages are expressed as the mean ± S.E. from at least four separate experiments. and * indicate
p < 0.0001.
|
|
Lactate Utilization--
The indication of a partial block in
lactate utilization was further explored by observing the response to
the infusion of [U-13C3]lactate. Infusion of
[U-13C3]lactate resulted in higher m3 lactate
enrichments in the fasted and fed states for the PPAR
KO mouse than
the corresponding fasted and fed values in the WT (Table
IV). The enrichment of
[U-13C3]lactate can be diluted by tissue
production of unlabeled lactate or by exchange through its
equilibration with pyruvate and alanine. Such dilution through isotope
exchange is of theoretical and practical concern, and for this reason,
even though our measurements are made at an isotopic steady state, we
will refer to lactate production measurements as the "apparent"
lactate production. Fig. 4 shows that a
50% decrease in the apparent lactate production in the fasted state
and a 75% decrease in the apparent lactate production in the fed state
was evident for the PPAR
KO mouse versus the WT control.
There was no significant difference in the lactate levels between the
PPAR
KO and WT mice in the fasted and fed states (Table II). Thus,
lactate utilization and/or isotopic exchange of lactate with alanine,
pyruvate, etc., is correspondingly decreased when PPAR
is
absent.
View this table:
[in this window]
[in a new window]
|
Table IV
Lactate and glycerol conversion for WT-C57BL/6 and PPAR
KO mice
Mice were fasted for 17 hours and refed standard laboratory chow for 5 hours. Statistical comparisons are between fasted values or fed values
only; fed and fasted values are not compared. * indicates
p < 0.01, and ** indicates p < 0.05.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 4.
HGP from lactate (see "Materials and
Methods," Equation 9) (top panel) and the lactate
production rate (see "Materials and Methods," Equation 4)
(bottom panel). Both were measured after 17 h of fasting and 5 h of refeeding for the PPAR KO mice and WT
C57BL/6 control using a [U-13C3]lactate
infusion administered by Alza miniosmotic pump (see "Materials and
Methods"). HGP and lactate production rates are expressed in terms of
mg produced/kg of body weight/minute as the mean ± S.E. from at
least four separate experiments. and indicate p < 0.05.
|
|
Glycerol Utilization--
Table IV shows the enrichment of m1
glycerol during the [2-13C]glycerol infusion. Infusion of
[2-13C]glycerol resulted in a 40% decrease in the
enrichment of m1 glycerol in the fasted state and a 30% decrease in
the enrichment of m1 glycerol in the fed state. The difference in
enrichment translates into a difference in the calculated rates of
glycerol production for the PPAR
KO mouse versus the
control. Fig. 5 shows that glycerol
production in the 17-h fasted state was 60-80% higher in the PPAR
KO mouse than the wild-type control. The conversion of triose-P to
pyruvate/lactate directly, or after its conversion to glucose, results
in m1 plasma lactate. The m1 plasma lactate enrichment for the PPAR
KO mouse, in response to the [2-13C]glycerol infusion, is
equivalent to the fraction of lactate produced from glycerol. This
lactate fractional production was 25% less in the fasted state and
15% less in the fed state than the wild-type control (Table IV). Thus,
despite the increased glycerol production, conversion of glycerol to
lactate is decreased for the fasted state and may also be decreased for
the fed state.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 5.
HGP from glycerol (see "Materials and
Methods," Equation 9) (top panel) and the glycerol
production rate (see "Materials and Methods," Equation 3)
(bottom panel). Both were measured after 17 h of fasting and 5 h of refeeding for the PPAR KO mice and WT
C57BL/6 control using a [U-13C6]glucose
infusion administered by Alza miniosmotic pump (see "Materials and
Methods"). HGP and glycerol production rates are expressed in terms
of mg produced/kg of body weight/minute as the mean ± S.E. from
at least four separate experiments. * and indicate
p < 0.01; indicates p < 0.02.
|
|
Enzymes of Pyruvate Substrate Cycle--
The demonstration of a
block in the conversion of lactate to glucose and glycerol to lactate
could indicate a block in the expression of enzymes in the PEP/pyruvate
substrate cycle that are sensitive to the metabolic state. Fig.
6 shows the expression of PEPCK and
pyruvate kinase in the fasted state of the PPAR
KO mouse
versus the wild-type control as measured using TAQMAN RT-PCR. While little change is evident for PEPCK expression, pyruvate kinase expression is decreased 16-fold with respect to the wild-type control (
CT ~4). These results suggest
that either PEPCK is not a key factor in mediating hepatic PPAR
action and/or posttranscriptional mechanisms may affect the
amount/regulation of flux between pyruvate and PEP. The decreased
pyruvate kinase expression is consistent with the decreased conversion
of glycerol to lactate.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
The effect of 17 h fast and 5 h
refeeding (standard chow) on hepatic PEPCK and pyruvate kinase mRNA
expression for the WT and PPAR KO mice.
Total RNA was extracted from liver obtained from mice of both strains
and analyzed by quantitative TAQMAN RT-PCR (PerkinElmer Life Sciences).
In comparison to the C57BL/6 control, the abundance of PEPCK, or
pyruvate kinase relative to that of -actin is
2 CT. The log2
(relative mRNA abundance change) is equivalent to the normalized
threshold cycle numbers,  CT (see
"Materials and Methods") and are expressed as the mean ± S.E.
from at least four separate experiments.
|
|
Substrates for Glucose Production--
In light of the results
indicating that PPAR
KO is hypoglycemic despite a mildly increased
HGP, we examined the rate of glucose synthesis from glycerol and
lactate. Results are shown in Figs. 4 and 5. For the PPAR
KO mouse,
hepatic glucose production from lactate was to be ~3-fold decreased
in either the fasted state or fed state as compared with the WT
control. Decreases in lactate production mirrored the changes in HGP
from lactate. Compensating for the reduced glucose production from
lactate, hepatic glucose production from glycerol was to be 2.5-fold
increased in the fasted state and 4-fold increased in the fed state for
PPAR
KO mice as compared with the WT controls. These results further
indicate profound changes in glucose, lactate, and glycerol fluxes and their utilization, when PPAR
is absent.
 |
DISCUSSION |
The PPAR
KO mouse is known to have defective fatty acid
-oxidation. It is considered to be an excellent model for the study of disorders of
-oxidation. PPAR
KO mice exhibit severe
hypoglycemia, hypoketonemia, hypothermia, and elevated FFA when fasted
(3, 4). It has long been suspected that the hypoglycemia is secondary to an impairment in hepatic gluconeogenesis due to a lack of obligatory cofactors (ATP, NADH, acetyl-CoA) resulting from decreased fatty acid
oxidation (5, 6). We have carried out stable isotope tracer studies to
investigate the substrate utilization for hepatic glucose production in
PPAR
KO mice. In the fasted state, blood glucose in the PPAR
KO
was maintained by a slightly elevated rate of hepatic glucose
production. Glucose carbon recycling was reduced, and gluconeogenic
fraction from lactate was only 66% as opposed to 51% for the WT. The
observation of reduced gluconeogenesis from lactate is consistent with
the 20% reduction of gluconeogenesis from lactate/pyruvate in
hepatocytes derived from the PPAR
KO mouse by Le May et
al. (5). When gluconeogenesis was estimated using
[2-13C]glycerol and MIDA, we found that the gluconeogenic
fraction contribution to blood glucose of PPAR
KO was comparable to
that of the WT control, being nearly 100%, suggesting sources other than lactate as significant gluconeogenic substrates.
Under conditions where the contribution of glycogenolysis to blood
glucose is minimal, lactate/pyruvate and gluconeogenic amino acids are
the predominant substrates for gluconeogenesis (18). Previous studies
suggest that the contribution that glycerol makes plays a minor role
(7, 19, 20). Our finding in the WT that HGP from glycerol being about
one-tenth of the total HGP is consistent with that view. The plasma
glycerol production rate (glycerol Ra) reflects mainly
adipose lipolysis (11, 21) because measurements of fatty acid turnover
have been found to be consistent with the production of glycerol from
the intracellular hydrolysis of triglycerides (reviewed in Ref. 21). In
long-term fasting, 15-20% of systemic glycerol turnover may not be
due to lipolysis of adipose tissue triglyceride but rather may be due
to the hydrolysis of triglyceride circulating as very low
density lipoprotein (22). Circulating glycerol is mostly taken up by
the liver and utilized for glucose production (15, 19, 20). Thus,
conditions that affect lipolysis can have a major influence on the
relative contribution of glycerol to gluconeogenesis. In experiments by
Jahoor et al. (23) inhibition of lipolysis with nicotinic
acid resulted in a 16-20% reduction in glucose production and a 50%
reduction in glycerol Ra. Glucose production was restored
by glycerol infusion alone (23). Work by Roden et al. (24)
indicates that only high FFA concentrations have a stimulatory effect
on gluconeogenesis. In the PPAR
KO, glycerol production rate after a
17-h fast was 80% higher than that in the WT. The contribution of
glycerol to gluconeogenesis when PPAR
was absent was correspondingly
increased to about 50% as compared with the 10% in the WT. In the
PPAR
KO, lactate production rate and the glucose production from
lactate was greatly reduced. The complementary relationship between
lactate production and glycerol production readily suggests the
existence of two futile cycles between 3-carbon substrates (glycerol
and lactate) and 6-carbon substrate (glucose and glycogen) as depicted in Fig. 7. The cycling between
lactate/pyruvate and glucose is the well known Cori cycle, which serves
to transport energy from the liver to the peripheral tissues as
glucose. In the process, 3-carbon substrates are conserved. On the
other hand, the cycling between glycerol and glucose has been less well
appreciated. The glycerol cycle also transports energy fuel substrate
in the form of triglycerides. However, fatty acid
-oxidation in
peripheral tissues and the liver is required. The interaction between
these two futile cycles has not been well characterized. In the PPAR
KO fasted for 24 h, the reduced
-oxidation was associated with elevation of FFA, which may also reflect increased lipolysis (3). Whether the increased FFA, the reduced
-oxidation, or the elevated glycerol production inhibits lactate production and gluconeogenesis from lactate in the fasted state, or liver glycogen synthesis in the
fed state, remains to be investigated.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 7.
The Cori cycle between lactate/pyruvate and
glucose serves to transport energy from the liver to peripheral tissues
as glucose. The glucose/glycerol cycle exists primarily between
the adipose tissue and the liver. Our data indicate the existence of an
interaction between these two futile cycles, dependent on the presence
of PPAR . The increased width of the hepatic glycerol flux arrow and
the decreased width of muscle lactate flux arrow reflect the changes
seen for the PPAR KO mouse glucose metabolome. The PPAR KO mouse
has a less active Cori cycle and a more active glucose/glycerol cycle
compared with the WT (LPL, lipoprotein lipase;
HSL, hormone-sensitive lipase). Note that the hypoglycemia
seen in the fasted and fed states for the PPAR KO mouse, despite
increased hepatic glucose production, implies the possibility of
increased glucose utilization by muscle.
|
|
PPAR
KO mice generally do not survive a relatively prolonged fast.
This leads to the belief that PPAR
is crucial for maintaining energy
homeostasis in the adaptive response to fasting (reviewed in Refs. 1,
2). Since insulin is an important hormone that regulates glucose
metabolism in the transition from the fasted to fed state, a few
studies have been done to examine the role of PPAR
in modulating
insulin sensitivity and resistance (6, 25, 26). Results of such studies
are conflicting. While PPAR
activators have been shown to improve
insulin sensitivity, (25) under the conditions of high fat feeding the
absence of PPAR
seems to negate the development of high-fat
diet-induced insulin resistance (6, 26). Our data indicate that for the
PPAR
KO mouse under the physiologic conditions of refeeding, HGP is increased and glycogen synthesis is decreased for the same insulin levels, suggesting a situation of hepatic insulin resistance. Our
results are consistent with the finding that PPAR
activators improve
insulin sensitivity by Guerre-Millo et al. (25). However, our observation is opposite to the conclusion of Tordjman et
al. (26) in their studies of PPAR
KO mice with a ApoE KO mouse background. Our study of metabolic adaptation to the fast and fed cycle
revealed for the first time that the absence of PPAR
affects
substrate utilization regardless of the level of insulin. Abnormalities
of glucose metabolism, particularly reduced lactate production and
glycogen synthesis, are more pronounced in the fed than in the fasted
state. The lack of glucose carbon recycling via the Cori cycle and the
depletion of liver glycogen in the liver when PPAR
is absent
promotes a maladaptation to prolonged fast.
In summary, our investigation into hypoglycemia in the PPAR
KO mice
points to the importance of studying the dynamics of substrate fluxes
of both the fed and fasted states. Metabolic abnormalities resulting
from specific gene defects may lead to specific abnormalities in
substrate fluxes, which limit the adaptation in the transition from
fasted to fed states. In the PPAR
KO mice, the metabolic abnormality
is probably initiated by the reduced lactate production and conversion
to glucose, leading to poor glycogen deposits in both the liver and in
the muscles. In the fasted state, PPAR
KO mice cannot switch to
fatty acid oxidation, which leads to reduced glucose carbon recycling
and continued depletion of 6-carbon substrates. Standard
characterization of phenotypes using the insulin tolerance test and the
intraperitoneal glucose tolerance test showed a silent phenotype
for the action of PPAR
(3, 26) and failed to reveal any difference
for the action of PPAR
on insulin action when chow fed. The PPAR
KO mouse is a complex glucose metabolic phenotype that can better be
understood in the context of glucose metabolome studies
(characterization of substrate fluxes within a glucose metabolic
network) than the paradigm of insulin sensitivity and insulin
resistance, as in traditional studies.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Alan R. Collins, Dept. of
Medicine, UCLA, for technical assistance. We are grateful to Dr. Frank
Gonzalez (NCI, National Institutes of Health) and Dr. Ron Evans (Salk
Institute) for the gift of the PPAR
KO mice.
 |
FOOTNOTES |
*
This work was supported by a grant from the American
Diabetes Association (to I. J. K.) and Grants DK56090-A1 (to
W. N. P. L.) and HL66088 (to P. T.). The GC/MS Facility is
supported by United States Public Health Service Grant
P01-CA42710 to the UCLA Clinical Nutrition Research Unit, Stable
Isotope Core and Grant M01-RR00425 to the General Clinical Research
Center.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§§
Assistant investigator of the Howard Hughes Medical
Institute at the University of California, Los Angeles, CA 90095.
¶¶
To whom correspondence should be addressed. Tel.:
818-634-6953; Fax: 310-825-8534; E-mail address:
irwinjk@earthlink.net.
Published, JBC Papers in Press, August 9, 2002, DOI 10.1074/jbc.M201208200
 |
ABBREVIATIONS |
The abbreviations used are:
PPAR, peroxisome
proliferator-activated receptor;
KO, knockout;
FFA, free fatty acids;
PEPCK, phosphoenolpyruvate carboxykinase;
HGP, hepatic glucose
production;
GC/MS, gas chromatography/mass spectrometry;
RT, reverse
transcription;
MIDA, mass isotopomer distribution analysis;
V-A, venous-arterial;
A-V, arterial-venous;
PEP, phosphoenolpyruvate;
triose-P, triose-phosphate;
WT, wild type.
 |
REFERENCES |
| 1.
|
Kersten, S.,
Desvergne, B.,
and Wahli, W.
(2000)
Nature
405,
421-424[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Desvergne, B.,
and Wahli, W.
(1999)
Endocr. Rev.
20,
649-688[Abstract/Free Full Text]
|
| 3.
|
Kersten, S.,
Seydoux, J.,
Peters, J. M.,
Gonzalez, F. J.,
Desvergne, B.,
and Wahli, W.
(1999)
J. Clin. Invest.
103,
1489-1498[Medline]
[Order article via Infotrieve]
|
| 4.
|
Leone, T. C.,
Weinheimer, C. J.,
and Kelly, D. P.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
7473-7478[Abstract/Free Full Text]
|
| 5.
|
Le May, C.,
Pineau, T.,
Bigot, K.,
Kohl, C.,
Girard, J.,
and Pegorier, J. P.
(2000)
FEBS Lett.
475,
163-166[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Guerre-Millo, M.,
Rouault, C.,
Poulain, P.,
Andre, J.,
Poitout, V.,
Peters, J. M.,
Gonzalez, F. J.,
Fruchart, J. C.,
Reach, G.,
and Staels, B.
(2001)
Diabetes
50,
2809-2814[Abstract/Free Full Text]
|
| 7.
|
Chomczynsky, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
|
| 8.
|
Szafranek, J.,
Pfaffenberger, D. C.,
and Horning, E. C.
(1974)
Carbohydr. Res.
38,
97-105[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Tserng, K. Y.,
Gilfillan, C. A.,
and Kalhan, S. C.
(1984)
Anal. Chem.
56,
517-523[Medline]
[Order article via Infotrieve]
|
| 10.
|
Lee, W. N. P.
(1989)
J. Biol. Chem.
264,
13002-13004
|
| 11.
|
Lee, W. N. P.,
Edmond, J.,
Byerley, L. O.,
and Bergner, E. A.
(1990)
Biol. Mass. Spectrom.
20,
451-458
|
| 12.
|
Wolfe, R. R.
(1992)
Radioactive and Stable Isotope Tracers in Biomedicine
, pp. 119-144, John Wiley & Sons, Inc., New York
|
| 13.
|
Katz, J.,
and Wolfe, R. R.
(1988)
Metabolism
37,
1078-1080[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Peroni, O.,
Large, V.,
Odeon, M.,
and Beylot, M.
(1996)
Metabolism
45,
897-901[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Landau, B. R.
(1999)
Am. J. Physiol.
277,
E408-E413[Free Full Text]
|
| 16.
|
Landau, B. R.,
Wahren, J.,
Ekberg, K.,
Previs, S. F.,
Yang, D.,
and Brunengraber, H.
(1998)
Am. J. Physiol.
274,
E954-E961[Abstract/Free Full Text]
|
| 17.
|
Hellerstein, M. K.,
and Neese, R. A.
(1999)
Am. J. Physiol.
276,
E1146-E1170[Abstract/Free Full Text]
|
| 18.
|
Exton, J. H.,
and Park, C. R.
(1967)
J. Biol. Chem.
242,
2622-2636[Abstract/Free Full Text]
|
| 19.
|
Landau, B. R.,
Wahren, J.,
Chandramouli, V.,
Schumann, W. C.,
Ekberg, K.,
and Kalhan, S. C.
(1996)
J. Clin. Invest.
98,
378-385[Medline]
[Order article via Infotrieve]
|
| 20.
|
Landau, B. R.,
Wahren, J.,
Previs, S. F.,
Ekberg, K.,
Chandramouli, V.,
and Brunengraber, H.
(1996)
Am. J. Physiol.
271,
E1110-E1117[Abstract/Free Full Text]
|
| 21.
|
Landau, B. R.
(1999)
Proc. Nutr. Soc.
58,
973-978[Medline]
[Order article via Infotrieve]
|
| 22.
|
Jensen, M. D.,
Chandramouli, V.,
Schumann, W. C.,
Ekberg, K.,
Previs, S. F.,
Gupta, S.,
and Landau, B. R.
(2001)
Am. J. Physiol. Endocrinol. Metab.
281,
E998-E1004[Abstrac |